What are the other Names for this Condition? (Also known as/Synonyms)

• Hyperzincemia/Hypercalprotectinemia (Hz/Hc)
• PAMI-AID
• PSTPIP1-Associated Myeloid-Related Proteinemia Inflammatory Syndrome (PAMI Syndrome)

What is PAMI Syndrome? (Definition/Background Information)

• PAMI Syndrome, also known as PSTPIP1-Associated Myeloid-Related Proteinemia Inflammatory Syndrome, is a rare autoinflammatory disorder caused by mutations in the PSTPIP1 gene. PSTPIP1 stands for proline-serine-threonine phosphatase-interacting protein 1 and is involved in regulating the function of immune cells
• PAMI Syndrome is characterized by recurrent episodes of fever, joint pain, skin rash, and inflammation in various organs and tissues. The symptoms typically start in infancy or early childhood, although the age of onset can vary. The frequency and severity of episodes can also vary among affected individuals
• In addition to the systemic inflammatory symptoms, PAMI Syndrome can also cause other features such as muscle pain, swelling of the lymph nodes, eye inflammation, and elevated levels of certain blood proteins, called myeloid-related proteins, specifically calprotectin. Serum zinc is also elevated
• PAMI Syndrome is inherited in an autosomal dominant manner, which means that a mutation in one copy of the PSTPIP1 gene is sufficient to cause the condition. In some cases, the syndrome may occur sporadically without a family history of the disorder
• The exact mechanisms by which mutations in the PSTPIP1 gene lead to the development of PAMI Syndrome are not fully understood. However, it is believed that the mutations disrupt the normal regulation of inflammation and immune responses, leading to the characteristic symptoms and features of the condition
• Diagnosis of PAMI Syndrome is typically based on clinical features and genetic testing to identify mutations in the PSTPIP1 gene, including excluding other similar conditions. Management of PAMI Syndrome involves the use of anti-inflammatory medications to control symptoms during episodes, as well as long-term monitoring and supportive care. The overall outcomes vary from one individual to another and is dependent on several factors
• If there is a suspicion of PAMI Syndrome based on symptoms and/or a family history of the condition, consultation with a healthcare professional or a specialist in genetics and autoinflammatory disorders is recommended. Genetic testing can be performed to identify mutations in the PSTPIP1 gene and confirm the diagnosis in affected individuals or assess the risk in at-risk family members

Who gets PAMI Syndrome? (Age and Sex Distribution)

• The exact prevalence and incidence of PAMI Syndrome are not well-established. It is considered to be extremely rare. As a result, the age and sex distribution of PAMI Syndrome may not be well-defined
• The age of onset can vary among affected individuals. The available literature suggests that PAMI Syndrome typically presents in early childhood, with symptoms often starting in infancy or early childhood. However, there have been reported cases of symptom onset in later childhood or adolescence
• Autoinflammatory disorders, in general, can affect both males and females. However, specific data on the sex distribution of PAMI Syndrome are not readily available due to its rarity

It is important to note that PAMI Syndrome is a relatively newly-described condition, and ongoing research may provide more insights into its epidemiology and demographic characteristics as more cases are reported and studied.

What are the Risk Factors for PAMI Syndrome? (Predisposing Factors)

PAMI Syndrome is primarily caused by mutations in the PSTPIP1 gene that are typically inherited in an autosomal dominant manner, meaning that a mutation in one copy of the gene is sufficient to cause the condition.

• Positive family history: The risk factors for developing PAMI Syndrome are primarily related to having a family history of the condition or carrying a pathogenic mutation in the PSTPIP1 gene. Individuals who have a parent or close relative with this disorder or a known PSTPIP1 mutation may have an increased risk of developing the condition themselves. Although, in some cases, PAMI Syndrome may occur sporadically without a family history of the disorder
• It is important to note that PAMI Syndrome is a rare disorder, and the exact prevalence and incidence are not well-established. The specific factors that contribute to the occurrence of PSTPIP1 gene mutations are not yet fully understood

It is important to note that having a risk factor does not mean that one will get the condition. A risk factor increases one’s chances of getting a condition compared to an individual without the risk factors. Some risk factors are more important than others. 

Also, not having a risk factor does not mean that an individual will not get the condition. It is always important to discuss the effect of risk factors with your healthcare provider.

What are the Causes of PAMI Syndrome? (Etiology)

Mutations in the PSTPIP1 gene primarily cause PAMI Syndrome. It is typically inherited in an autosomal dominant manner. In some cases, PAMI Syndrome may occur sporadically without a family history of the disorder due to de novo (new) mutations.

• The PSTPIP1 gene provides instructions for making a protein called proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1 protein). This protein is involved in regulating the function of immune cells, particularly in the inflammatory response
• The exact mechanisms by which mutations in the PSTPIP1 gene lead to the development of PAMI Syndrome are not fully understood. However, it is believed that the mutations disrupt the normal regulation of inflammation and immune responses, leading to the characteristic symptoms and features of the condition
• The same PSTPIP1 gene has mutations seen in other autoinflammatory diseases, which are more severe than PAMI Syndrome. The mutation in the PSTPIP1 gene in PAMI Syndrome is named E250K
• The PSTPIP1 protein interacts with other proteins involved in the immune system, such as pyrin and actin-binding proteins. The specific signaling chemical elevated in PAMI is “alarmin”, the first clinical disease associated with this biochemical. It is thought that mutations in the PSTPIP1 gene may disrupt these interactions and dysregulate the inflammatory pathways, resulting in excessive inflammation and the clinical manifestations seen in PAMI Syndrome.

Autosomal dominant: Autosomal dominant conditions are traits or disorders that are present when only one copy of the mutation is inherited on a non-sex chromosome. In these types of conditions, the individual has one normal copy and one mutant copy of the gene. The abnormal gene dominates, masking the effects of the correctly function gene. If an individual has an autosomal dominant condition, the chance of passing the abnormal gene on to their offspring is 50%. Children, who do not inherit the abnormal gene, will not develop the condition or pass it on to their offspring.

It is important to note that PAMI Syndrome is rare, and further research is needed to understand the underlying causes and mechanisms fully. Genetic testing and counseling are crucial for confirming the diagnosis, understanding the inheritance pattern, and providing appropriate management and support for affected individuals and their families.

What are the Signs and Symptoms of PAMI Syndrome?

The signs and symptoms of PAMI Syndrome can vary among affected individuals but typically involve recurrent episodes of fever, inflammation, and organ involvement. Some common signs and symptoms associated with the syndrome include:

• Recurrent fever: Individuals may experience recurrent fever episodes, which can occur spontaneously or be triggered by certain factors. Fevers are often high-grade and can be accompanied by other symptoms
• Inflammatory skin manifestations: Skin manifestations are commonly observed in PAMI Syndrome and can include erythematous (red) patches or nodules, pustules, or other forms of skin inflammation. The skin involvement may resemble conditions such as pustular psoriasis or pyoderma gangrenosum
• Joint pain and swelling: Joint involvement is common, leading to joint pain, swelling, and stiffness. Multiple joints can be affected, and the symptoms may resemble infectious, bacterial arthritis
• A key feature of PAMI Syndrome is a decrease in the formed elements of blood - red blood cells, platelets, and all types of white blood cells. One or all of these cells may decrease. Low blood cell levels can cause severe anemia, bleeding risk, and susceptibility to infection
• Splenomegaly (enlarged spleen) and hepatomegaly (enlarged liver) are frequent findings
• Eye inflammation: Inflammation of the eyes, such as uveitis or conjunctivitis, can occur in individuals with PAMI Syndrome. This can lead to redness, eye pain, sensitivity to light, and blurred vision
• Muscle pain: Some individuals may experience muscle pain or myalgia, which can be generalized or localized to specific muscle groups
• Lymph node enlargement: Swelling and enlargement of the lymph nodes can occur during episodes of inflammation
• Elevated myeloid-related proteins: Blood tests may reveal elevated levels of certain proteins, such as myeloid-related proteins (MRP8 and MRP14), which are markers of inflammation.
• Pulmonary hypertension was found in one patient

It is important to note that the signs and symptoms of PAMI Syndrome can overlap with other autoinflammatory disorders, making the diagnosis challenging. Genetic testing is necessary to confirm the presence of mutations in the PSTPIP1 gene and establish a definitive diagnosis.

How is PAMI Syndrome Diagnosed?

The diagnosis of PAMI Syndrome typically involves a combination of clinical evaluation, genetic testing, and exclusion of other similar conditions. Given the rarity of PAMI Syndrome, it is important to consult with healthcare professionals experienced in autoinflammatory disorders and genetics for an accurate diagnosis. The diagnostic process may involve:

• Clinical evaluation: A thorough evaluation of the individual's medical history, symptoms, and physical examination is conducted. The presence of recurrent fevers, inflammatory skin manifestations, joint involvement, eye inflammation, muscle pain, and other characteristic symptoms may raise suspicion for PAMI Syndrome
• Family history evaluation: Evaluation of the family history is important to determine if there is a pattern of inheritance or if other family members are affected
• Genetic testing: Genetic testing is the definitive method to confirm the diagnosis of PAMI Syndrome. It involves analyzing the PSTPIP1 gene for pathogenic mutations. This is typically done through targeted gene sequencing or more comprehensive genetic testing panels that include autoinflammatory genes
• Exclusion of other conditions: As the symptoms of PAMI Syndrome can overlap with other autoinflammatory disorders, it is essential to rule out alternative diagnoses. This may involve additional laboratory tests, imaging studies, or consultations with relevant specialists
• Genetic counseling: Genetic counseling is an integral part of the diagnostic process for PAMI Syndrome. Genetic counselors can provide information about the inheritance pattern, recurrence risks, and available family planning options based on the identified genetic mutation.

If PAMI Syndrome is suspected, it is recommended to consult with a healthcare professional to initiate the diagnostic process and receive personalized care.

What are the possible Complications of PAMI Syndrome?

The specific complications arising from PAMI Syndrome can vary in severity and occurrence among affected individuals. Some potential complications associated with the condition include:

• Joint destruction: Inflammation of the joints can lead to progressive joint damage, deformities, and limitations in mobility. If left untreated or inadequately managed, this can result in long-term joint complications, including disability
• Vision loss: Eye inflammation, such as uveitis, can lead to complications such as vision loss, cataracts, glaucoma, or retinal damage. Regular ophthalmologic evaluation and appropriate treatment are crucial to prevent or manage these complications
• Organ damage: The recurrent episodes of inflammation in PAMI Syndrome can potentially lead to organ damage over time. The severity and specific organs affected can vary among individuals. Organs commonly involved include the skin, joints, eyes, and gastrointestinal tract
• Impaired quality of life: The chronic nature of the syndrome and the recurrent episodes of symptoms can significantly impact the individual's quality of life. The unpredictable nature of the disease, pain, fatigue, and limitations in daily activities can affect social interactions, education, employment, and overall well-being
• Developmental and learning challenges: It can be associated with developmental delays, intellectual disability, and learning challenges. The impact on cognitive abilities, educational attainment, and overall developmental outcomes can vary among affected individuals
• Psychosocial effects: Living with a chronic and unpredictable condition can have psychological and emotional implications. Individuals may experience anxiety, depression, social isolation, and difficulties coping with the impact of the disease

Regular medical follow-up, adherence to treatment regimens, and ongoing communication with healthcare professionals are essential in monitoring potential complications and addressing them promptly when they arise.

How is PAMI Syndrome Treated?

PAMI Syndrome is an autoinflammatory disorder for which no specific cure exists. The treatment for this syndrome aims to manage symptoms, control inflammation, and improve the individual's quality of life. The treatment approach is often individualized based on each affected person's specific symptoms and needs. Here are some general treatment strategies:

• Medications to control inflammation: Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may be prescribed to help manage pain, reduce inflammation, and control fever during episodes. In more severe cases or when NSAIDs are insufficient, corticosteroids or other immunosuppressive medications may be used to dampen the inflammatory response
• Disease-modifying anti-rheumatic drugs (DMARDs): Certain DMARDs, such as methotrexate, may be prescribed to help control inflammation and prevent disease flares. These medications are often used for individuals who have inadequate responses to NSAIDs alone or require long-term management
• Biologic therapies: In some cases, biologic therapies that target specific molecules involved in inflammation, such as interleukin-1 (IL-1) inhibitors or interleukin-6 (IL-6) inhibitors, may be considered. These medications can help reduce inflammation and control symptoms in individuals who do not respond well to other treatments. The interleukin-1 inhibitor anakina improved the joint and other signs but not the bone marrow involvement
• In a report with three cases, one responded well to methylprednisone and cyclosporin together. Another responded to etanercept and methylprednisolone. The third did well with methylprednisolone, methotrexate, and infliximab.
• Symptom management: Depending on the symptoms present, additional medications or interventions may be used to manage specific manifestations of PAMI Syndrome. For example, medications may be prescribed to control eye inflammation (uveitis), joint pain, or skin manifestations
• Supportive care: Supportive care measures aim to improve the individual's overall well-being and quality of life. This may include pain management strategies, physical therapy to maintain or improve mobility, occupational therapy to support daily activities, and psychosocial support to address the emotional and psychological impact of the condition
• Regular monitoring: Regular medical follow-up is essential to monitor the individual's symptoms, disease activity, and response to treatment. Medications or treatment plans may be adjusted based on the individual's specific needs

Given the rarity of PAMI Syndrome, consulting with healthcare professionals experienced in autoinflammatory disorders and genetics is crucial for accurate diagnosis and management. Supportive care, including pain management, rehabilitation, and psychosocial support, can also play a significant role in managing the complications associated with PAMI Syndrome

It is important for individuals with PAMI Syndrome to work closely with healthcare professionals experienced in autoinflammatory disorders to receive appropriate treatment and care. The treatment approach may evolve over time as new therapies and research emerge. Close communication with the healthcare team, adherence to treatment plans, and ongoing monitoring are crucial for managing symptoms and optimizing outcomes.

How can PAMI Syndrome be Prevented?

PAMI Syndrome is a genetic disorder and is not currently preventable in terms of avoiding its onset or occurrence. The mutations in the PSTPIP1 gene responsible for PAMI Syndrome occur spontaneously and are not influenced by external factors or behaviors.

However, there are steps that can be taken to manage and reduce the impact of the disorder:

• Early diagnosis and treatment: Early diagnosis and prompt initiation of appropriate treatment can help manage symptoms, control inflammation, and minimize complications. Seeking medical attention when symptoms arise or when there is a family history of PAMI Syndrome can facilitate early intervention
• Regular medical monitoring: Regular medical check-ups and monitoring are essential for individuals with PAMI Syndrome. This allows healthcare professionals to closely monitor disease activity, adjust treatment plans as needed, and address any emerging complications or symptoms
• Medication adherence: Adhering to prescribed medications as directed by healthcare professionals is crucial for managing symptoms and preventing disease flares. Consistent and appropriate use of medications can help control inflammation and reduce the frequency and severity of episodes.
• Lifestyle and self-care: Engaging in a healthy lifestyle, including regular exercise, a balanced diet, and adequate rest, can support overall well-being and possibly reduce the impact of symptoms. Self-care practices, such as stress management techniques and seeking emotional support, can also contribute to better disease management
• Genetic counseling: Genetic counseling is recommended for individuals with PAMI Syndrome or families with a known mutation in the PSTPIP1 gene. Genetic counselors can provide information about inheritance patterns, recurrence risks, and family planning options

It is important to note that while PAMI Syndrome cannot be prevented, understanding the genetic basis of the condition and its inheritance pattern can help individuals and families make informed decisions about family planning and reproductive options.

As research advances, future developments in gene therapies or targeted interventions may provide potential preventive or disease-modifying strategies. However, these approaches are still in the early stages of development and are not widely available at present.

Individuals and families affected by PAMI Syndrome should consult with healthcare professionals experienced in autoinflammatory disorders and genetics for personalized guidance and support.

What is the Prognosis of PAMI Syndrome? (Outcomes/Resolutions)

The prognosis of PAMI Syndrome can vary among affected individuals. Due to the rarity of the condition and limited available data, predicting the long-term outcomes and disease course can be challenging. However, here are some considerations regarding the prognosis of PAMI Syndrome:

• Variable disease course: The disease course of PAMI Syndrome can vary widely among individuals. Some individuals may experience milder and more manageable symptoms, while others may have more severe and debilitating manifestations. The frequency and severity of episodes can also differ among affected individuals
• Symptom management: With appropriate treatment and management, symptoms of PAMI Syndrome can often be controlled, allowing individuals to lead relatively normal lives between episodes. Medications, such as NSAIDs, corticosteroids, DMARDs, and biologic therapies, may be used to manage inflammation and control symptoms. Regular monitoring and adjustment of treatment plans may be necessary to optimize symptom management
• Complications and organ involvement: The risk of complications in PAMI Syndrome depends on the severity and frequency of inflammation and the specific organs affected. Prompt diagnosis, effective treatment, and regular monitoring can help mitigate these complications
• Impact on quality of life: PAMI Syndrome can significantly impact the quality of life of affected individuals. Recurrent episodes of fever, pain, and inflammation, as well as associated complications, can disrupt daily activities, education, employment, and social interactions. Supportive care measures, including pain management, physical therapy, and psychosocial support, can help improve quality of life
• Ongoing research: PAMI Syndrome is a relatively newly described condition, and ongoing research is needed further to understand the disease's long-term outcomes and natural progression. As more cases are identified and studied, more information regarding prognosis and management will likely become available.
• It is important for individuals with PAMI Syndrome to have regular follow-ups with healthcare professionals experienced in autoinflammatory disorders. This allows for ongoing monitoring of symptoms, adjustment of treatment plans, and addressing any emerging complications promptly. Open communication with the healthcare team and adherence to treatment regimens is crucial for optimizing outcomes and improving the prognosis.

Early diagnosis, appropriate management, and access to comprehensive care from a multidisciplinary team experienced in autoinflammatory disorders can help minimize complications and optimize outcomes.

Additional and Relevant Useful Information for PAMI Syndrome:

Since PAMI Syndrome is rare, connecting with patient support groups and organizations dedicated to autoinflammatory disorders can provide valuable resources, information, and a sense of community for individuals and families affected by PAMI Syndrome.

Other PSTPIP1 gene-associated diseases include:

• PASH
• PASS
• PAPA 
• PsAPASH
• PAC
• PAPASH